1,3-diphenylurea profile

1,3-Diphenylurea is a white crystalline solid. It has been investigated for its potential biological activity, including anti-inflammatory, analgesic, and anti-cancer effects. The compound is typically synthesized through the reaction of aniline with phenyl isocyanate. Its unique structure and potential pharmacological properties have driven research interest in exploring its applications.'

1,3-diphenylurea : A member of the class of phenylureas that is urea in which one of the hydrogens of each amino group is replaced by a phenyl group. It is present in coconut milk (Cocos nucifera). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	7595
CHEMBL ID	354676
CHEBI ID	41320
SCHEMBL ID	133103
SCHEMBL ID	21313806

Synonym
EU-0067898
smr000112141
AC-12855
MLS002207104
BRD-K13027645-001-02-0
1,3-diphenylurea
n-phenyl-n'-phenylurea
n,n'-diphenylurea
carbanilide
nsc-8485
acardite i
urea,n'-diphenyl-
urea,3-diphenyl-
nsc8485
s-diphenylurea
usaf ek-534
wln: rmvmr
102-07-8
nsc-227401
nsc227401
DIVK1C_006502
KBIO1_001446
ICCB1_000093
SDCCGMLS-0066513.P001
inchi=1/c13h12n2o/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1-10h,(h2,14,15,16
SPECTRUM_000422
urea, n,n'-diphenyl-
CBDIVE_002165
diphenylurea
OPREA1_527136
SPECTRUM5_000182
urea-based compound, 7
bdbm25725
NCGC00091344-01
AQ-917/40171059
ai3-52320
brn 0782650
urea, 1,3-diphenyl-
acardite
hsdb 2757
einecs 203-003-7
ad 30
ccris 4634
nsc 227401
n,n'-difenylmocovina [czech]
karbanilid [czech]
1,3-diphenylurea, 98%
NCGC00091344-02
KBIO2_003470
KBIO2_000902
KBIO3_002275
KBIOSS_000902
KBIOGR_002082
KBIO2_006038
SPECTRUM3_001328
SPECPLUS_000406
SPECTRUM2_001838
SPECTRUM4_001561
SPBIO_001915
SPECTRUM211126
BSPBIO_003055
NCGC00091344-03
CHEBI:41320 ,
diphenylcarbamide
sym-diphenylurea
1,3-diphenylcarbamide
STK328350
NCGC00091344-04
AKOS000312994
DB07496
1,3-diphenyl-urea
CHEMBL354676
KINOME_598
KINOME_627
NCGC00091344-05
n'n'-diphenyl urea
cas-102-07-8
NCGC00257622-01
dtxsid2025183 ,
dtxcid305183
tox21_200068
CCG-38465
karbanilid
n,n'-difenylmocovina
4-12-00-00741 (beilstein handbook reference)
unii-94yd8rmx5b
94yd8rmx5b ,
FT-0606720
2ZJF
diphenylurea, 1,3-
carbanilide [hsdb]
carbanilide [mi]
SCHEMBL133103
3E85
bis-phenyl-urea
n,n'-diphenyl urea
n, n'-diphenylurea
W-108886
mfcd00003017
SR-01000398115-1
SR-01000398115-2
sr-01000398115
1,3-diphenylurea, vetec(tm) reagent grade, 98%
1,3-diphenylurea\|carbanalide
1, 3-diphenylurea
n,n'-diphenyl-urea
zeonet u
rkl10128
1 pound not3-diphynylurea
F20340
Q27096716
SCHEMBL21313806
FS-4202
GEO-04213
n,n'-bis-phenylurea
n,n'-diphenylurea d10
carbanalide 100 microg/ml in acetonitrile
A896907
nsc794585
nsc-794585
CS-W015002
HY-W014286

Role	Description
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
cytokinin	A phytohormone that promote cell division, or cytokinesis, in plant roots and shoots.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
phenylureas	Any member of the class of ureas in which at least one of the nitrogens of the urea moiety is substituted by a phenyl or substituted phenyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	6.3571	0.0072	15.7588	89.3584	AID1224835
BRCA1	Homo sapiens (human)	Potency	15.8489	0.8913	7.7225	25.1189	AID624202
pregnane X receptor	Rattus norvegicus (Norway rat)	Potency	39.8107	0.0251	27.9203	501.1870	AID651751
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	6.2714	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
USP1 protein, partial	Homo sapiens (human)	Potency	1.2589	0.0316	37.5844	354.8130	AID504865
TDP1 protein	Homo sapiens (human)	Potency	16.4687	0.0008	11.3822	44.6684	AID686978; AID686979
AR protein	Homo sapiens (human)	Potency	13.7607	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588515; AID743042; AID743054; AID743063
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	39.8107	0.0013	18.0743	39.8107	AID926; AID938
hypothetical protein, conserved	Trypanosoma brucei	Potency	28.1838	0.2239	11.2451	35.4813	AID624173
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	5.4590	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	30.7625	0.0004	17.9460	75.1148	AID1346795
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	50.1187	0.0002	14.3764	60.0339	AID588533
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	2.8354	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	9.6031	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptor	Homo sapiens (human)	Potency	8.7324	0.0054	28.0263	1,258.9301	AID1346982; AID720659
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	17.4868	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743079; AID743080; AID743091
luciferase	Photuris pensylvanica (Pennsylania firefly)	Potency	11.2202	0.8913	10.4328	20.5750	AID1379
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	20.6770	0.0007	23.0674	1,258.9301	AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	1.2247	0.0017	23.8393	78.1014	AID743083
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	7.5059	0.3162	12.4435	31.6228	AID902; AID924
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	50.1187	3.5481	19.5427	44.6684	AID743266
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	21.7782	0.0003	23.4451	159.6830	AID743065
histone deacetylase 9 isoform 3	Homo sapiens (human)	Potency	1.7049	0.0376	17.0823	61.1927	AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	4.7308	0.0006	27.2152	1,122.0200	AID720636
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	11.2202	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	11.2202	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	11.2202	0.1585	5.2879	12.5893	AID540303
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	3.5481	0.0079	8.2332	1,122.0200	AID2546
geminin	Homo sapiens (human)	Potency	0.7308	0.0046	11.3741	33.4983	AID624297
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	12.8631	0.1259	12.2344	35.4813	AID1458
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.4876	0.0015	57.7890	15,848.9004	AID1259244
Integrin beta-3	Homo sapiens (human)	Potency	10.0000	0.3162	11.4157	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	10.0000	0.3162	11.4157	31.6228	AID924
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.4876	0.0015	51.7393	15,848.9004	AID1259244
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	0.8413	0.0266	22.4482	66.8242	AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Bifunctional epoxide hydrolase 2	Homo sapiens (human)	IC50 (µMol)	0.3950	0.0000	0.5450	9.1000	AID613884; AID755348
Tyrosine-protein kinase SYK	Homo sapiens (human)	IC50 (µMol)	660.0000	0.0001	0.8260	10.0000	AID613179
Epoxide hydrolase B	Mycobacterium tuberculosis CDC1551	IC50 (µMol)	0.0190	0.0190	0.6640	3.4000	AID1798579; AID613896
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Pr10.2b	Lupinus luteus (yellow lupine)	Kd	4.2000	4.2000	4.2000	4.2000	AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of leukocyte migration	Integrin alpha-IIb	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-IIb	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-IIb	Homo sapiens (human)
angiogenesis	Integrin alpha-IIb	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-IIb	Homo sapiens (human)
response to toxic substance	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
positive regulation of gene expression	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
dephosphorylation	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
cholesterol homeostasis	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
stilbene catabolic process	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
phospholipid dephosphorylation	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
regulation of cholesterol metabolic process	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
epoxide metabolic process	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
protein import into nucleus	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
angiogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
cell activation	Tyrosine-protein kinase SYK	Homo sapiens (human)
lymph vessel development	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of receptor internalization	Tyrosine-protein kinase SYK	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
macrophage activation involved in immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
neutrophil activation involved in immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
leukocyte activation involved in immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
serotonin secretion by platelet	Tyrosine-protein kinase SYK	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase SYK	Homo sapiens (human)
leukocyte cell-cell adhesion	Tyrosine-protein kinase SYK	Homo sapiens (human)
integrin-mediated signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
animal organ morphogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of platelet activation	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase SYK	Homo sapiens (human)
leukotriene biosynthetic process	Tyrosine-protein kinase SYK	Homo sapiens (human)
calcium-mediated signaling	Tyrosine-protein kinase SYK	Homo sapiens (human)
platelet activation	Tyrosine-protein kinase SYK	Homo sapiens (human)
B cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
neutrophil chemotaxis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Tyrosine-protein kinase SYK	Homo sapiens (human)
receptor internalization	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of type I interferon production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-10 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-12 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-3 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-4 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-6 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of interleukin-8 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of mast cell cytokine production	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of superoxide anion generation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of superoxide anion generation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Tyrosine-protein kinase SYK	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase SYK	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
Fc-epsilon receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase SYK	Homo sapiens (human)
interleukin-3-mediated signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
gamma-delta T cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
defense response to bacterium	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	Tyrosine-protein kinase SYK	Homo sapiens (human)
mast cell degranulation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of mast cell degranulation	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of neutrophil degranulation	Tyrosine-protein kinase SYK	Homo sapiens (human)
beta selection	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of MAPK cascade	Tyrosine-protein kinase SYK	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of B cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of gamma-delta T cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of bone resorption	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of alpha-beta T cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of alpha-beta T cell proliferation	Tyrosine-protein kinase SYK	Homo sapiens (human)
blood vessel morphogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of phagocytosis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Tyrosine-protein kinase SYK	Homo sapiens (human)
B cell receptor signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of killing of cells of another organism	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to molecule of fungal origin	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to lipid	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 production	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of arachidonic acid secretion	Tyrosine-protein kinase SYK	Homo sapiens (human)
regulation of platelet aggregation	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Tyrosine-protein kinase SYK	Homo sapiens (human)
positive regulation of TORC1 signaling	Tyrosine-protein kinase SYK	Homo sapiens (human)
cellular response to lectin	Tyrosine-protein kinase SYK	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase SYK	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase SYK	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin alpha-IIb	Homo sapiens (human)
identical protein binding	Integrin alpha-IIb	Homo sapiens (human)
metal ion binding	Integrin alpha-IIb	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-IIb	Homo sapiens (human)
molecular adaptor activity	Integrin alpha-IIb	Homo sapiens (human)
fibrinogen binding	Integrin alpha-IIb	Homo sapiens (human)
integrin binding	Integrin alpha-IIb	Homo sapiens (human)
magnesium ion binding	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
epoxide hydrolase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
toxic substance binding	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
lipid phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
protein homodimerization activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
lysophosphatidic acid phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
phosphotyrosine residue binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein serine/threonine kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
integrin binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
interleukin-15 receptor binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
kinase activity	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein kinase binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
phosphatase binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
Toll-like receptor binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
SH2 domain binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase SYK	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
focal adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell surface	Integrin alpha-IIb	Homo sapiens (human)
platelet alpha granule membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular exosome	Integrin alpha-IIb	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin alpha-IIb	Homo sapiens (human)
blood microparticle	Integrin alpha-IIb	Homo sapiens (human)
integrin complex	Integrin alpha-IIb	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
peroxisome	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
peroxisomal matrix	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
cytosol	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
extracellular exosome	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
peroxisome	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase SYK	Homo sapiens (human)
nucleus	Tyrosine-protein kinase SYK	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase SYK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase SYK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase SYK	Homo sapiens (human)
early phagosome	Tyrosine-protein kinase SYK	Homo sapiens (human)
B cell receptor complex	Tyrosine-protein kinase SYK	Homo sapiens (human)
protein-containing complex	Tyrosine-protein kinase SYK	Homo sapiens (human)
T cell receptor complex	Tyrosine-protein kinase SYK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase SYK	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay ID	Title	Year	Journal	Article
AID613167	Inhibition of PI3Kalpha expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1188916	Cytotoxicity against african green monkey Vero cells after 2 days by resazurin assay	2014	ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8	Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.
AID613145	Inhibition of JNK1 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613148	Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314135	Induction of membrane lysis in Staphylococcus aureus UL12 lipid vesicles assessed as calcein release at 3000 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613150	Inhibition of AurA expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613168	Inhibition of PI3Kdelta expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613160	Inhibition of ITK expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314138	Induction of membrane lysis in Escherichia coli W3110 lipid vesicles assessed as calcein release at 375 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314141	Induction of membrane lysis in Escherichia coli W3110 lipid vesicles assessed as calcein release at 3000 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314131	Induction of membrane lysis in Staphylococcus aureus UL12 lipid vesicles assessed as calcein release at 187.5 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613172	Inhibition of SGK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613170	Inhibition of RIP2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by fluorescence polarization assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1861243	Inhibition of PTPC in human AC16 cells at 1 uM measured by calcein-cobalt assay relative to control
AID613161	Inhibition of JAK3 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314147	Membrane permeabilisation in Escherichia coli W3110 assessed as NPN uptake at 2mM incubated overnight by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314145	Membrane permeabilisation in Escherichia coli W3110 assessed as NPN uptake at 2mM incubated for 1 hr by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314143	Antibacterial activity against Escherichia coli W3110	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314133	Induction of membrane lysis in Staphylococcus aureus UL12 lipid vesicles assessed as calcein release at 750 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314142	Antibacterial activity against Staphylococcus aureus UL12	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613158	Inhibition of GSK3-beta expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 667 uM by fluorescence polarization assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314144	Membrane permeabilisation in Staphylococcus aureus UL12 assessed as NPN uptake at 2mM incubated for 1 hr by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1314146	Membrane permeabilisation in Staphylococcus aureus UL12 assessed as NPN uptake at 2mM incubated overnight by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613151	Inhibition of AurB expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1314130	Induction of membrane lysis in Staphylococcus aureus UL12 lipid vesicles assessed as calcein release at 93.73 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613159	Inhibition of IGF1R expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613143	Inhibition of IKK-beta expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613154	Inhibition of FES expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 400 uM by fluorescence polarization assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613156	Inhibition of ErbB4 expressed in Escherichia coli or baculovirus-infected insect cells at 400 to 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613895	Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613149	Inhibition of ASK1 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613144	Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613169	Inhibition of PIM1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID755348	Inhibition of human recombinant soluble epoxide hydrolase using (cyano(6-methoxy-naphthelen-2-yl)methyl trans-[(3-phenyl-oxiran-2-yl)methyl] carbonate) as substrate preincubated for 5 mins prior to substrate addition by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.
AID613166	Inhibition of PDK1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1188918	Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum K1	2014	ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8	Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.
AID613179	Inhibition of SYK expressed in Escherichia coli or baculovirus-infected insect cells by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613171	Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1188914	Antimalarial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR Green fluorescence assay	2014	ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8	Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.
AID613153	Inhibition of EGFR expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314137	Induction of membrane lysis in Escherichia coli W3110 lipid vesicles assessed as calcein release at 187.5 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613165	Inhibition of PAK2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314134	Induction of membrane lysis in Staphylococcus aureus UL12 lipid vesicles assessed as calcein release at 1500 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613157	Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID396095	Inhibition of NorA efflux pump in Staphylococcus aureus K2361 assessed as reduction of ethidium bromide efflux at 0.5 uM for 5 mins	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
AID613896	Inhibition of Mycobacterium tuberculosis recombinant EphB expressed in Escherichia coli BL21 using CMNPC as substrate after 30 mins by fluorescent assay relative to control	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1314140	Induction of membrane lysis in Escherichia coli W3110 lipid vesicles assessed as calcein release at 1500 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613155	Inhibition of ErbB2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613173	Inhibition of SYK expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID613152	Inhibition of B-Raf expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 400 uM by fluorescence polarization assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1504503	Drug level in pH 7.4 PBS buffer treated with 2,4-Diphenyl-1,2,4-thiadiazoline-3,5-dione at 0.5 mmol after 5 to 60 mins in presence of cysteine by HPLC-MS analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	1,2,4-Thiadiazolidin-3,5-diones as novel hydrogen sulfide donors.
AID1314136	Induction of membrane lysis in Escherichia coli W3110 lipid vesicles assessed as calcein release at 93.73 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613147	Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1188915	Antimalarial activity against Plasmodium falciparum K1 after 72 hrs by SYBR Green fluorescence assay	2014	ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8	Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.
AID613163	Inhibition of p38alpha expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID1314132	Induction of membrane lysis in Staphylococcus aureus UL12 lipid vesicles assessed as calcein release at 375 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID1188917	Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum 3D7	2014	ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8	Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.
AID1314139	Induction of membrane lysis in Escherichia coli W3110 lipid vesicles assessed as calcein release at 750 uM by spectrofluorometric analysis	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Functional foldamers that target bacterial membranes: The effect of charge, amphiphilicity and conformation.
AID613884	Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate after 10 mins by fluorescent assay	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID613162	Inhibition of MK2 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by IMAP assay	2011	Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14	Selectivity of kinase inhibitor fragments.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID493040	Navigating the Kinome	2011	Nature chemical biology, Apr, Volume: 7, Issue:4	Navigating the kinome.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2009	The FEBS journal, Mar, Volume: 276, Issue:6	Cytokinin-induced structural adaptability of a Lupinus luteus PR-10 protein.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1798579	Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\	2008	Journal of molecular biology, Sep-12, Volume: 381, Issue:4	The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2011	Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18	The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (21.05)	29.6817
2010's	12 (63.16)	24.3611
2020's	3 (15.79)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.26%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (94.74%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.06	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide [no description available]	2.06	1	hydroxycinnamic acid
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.1	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.04	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
n(6),n(6)-dimethyladenine N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.	2.06	1	tertiary amine
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.08	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
go 6976 [no description available]	2.06	1	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
gw8510 GW8510: 3' substituted indolone as a scaffold for the development of neuroprotective drug; structure in first source	2.06	1
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide [no description available]	2.06	1	bromobenzenes; isoquinolines; olefinic compound; secondary amino compound; sulfonamide	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.06	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	2.06	1	carbohydrazide	antitubercular agent; drug allergen
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.06	1	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.06	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
1,3-dicyclohexylurea 1,3-dicyclohexylurea: degradation product of 1-(2-chloroethyl)-3- cyclohexyl-1-nitrosourea; structure	2.04	1	ureas
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.04	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.06	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
3,3',4,5'-tetrahydroxystilbene [no description available]	2.06	1	stilbenoid
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.06	1	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.06	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063 SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.	2.06	1	imidazoles
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.06	1	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
imatinib [no description available]	2.06	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.06	1	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	2.04	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
triclocarban triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure. triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively.	2.46	2	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.06	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.06	1	indazole
7-azaindole [no description available]	2.06	1	pyrrolopyridine
diphenylamine Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.. diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.	2.06	1	aromatic amine; bridged diphenyl fungicide; secondary amino compound	antifungal agrochemical; antioxidant; carotogenesis inhibitor; EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor; ferroptosis inhibitor; radical scavenger
1H-indazol-3-amine 1H-indazol-3-amine: structure in first source	2.06	1	indazoles
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.06	1	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
norharman norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.	2.06	1	beta-carbolines; mancude organic heterotricyclic parent	fungal metabolite; marine metabolite
mmv665852 MMV665852: an antischistosomal agent	2.04	1
eupatorin eupatorin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source. eupatorin : A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups.	2.06	1	dihydroxyflavone; polyphenol; trimethoxyflavone	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; Brassica napus metabolite; calcium channel blocker; P450 inhibitor; vasodilator agent
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	2.08	1	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
gefitinib [no description available]	2.06	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
ns 1608 NS 1608: a BK(Ca) channel opener	2.06	1	ureas
vatalanib [no description available]	2.06	1	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
birb 796 [no description available]	2.06	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
sb 203580 [no description available]	2.06	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
erlotinib [no description available]	2.06	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
orantinib [no description available]	2.06	1	monocarboxylic acid; oxindoles; pyrroles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
lapatinib [no description available]	2.06	1	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
sorafenib [no description available]	2.06	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.06	1
diphenylthiourea N,N'-diphenylthiourea : Thiourea in which each nitrogen carries a phenyl substituent.	2.1	1	thioureas	allergen
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol [no description available]	2.06	1	substituted aniline
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide 3-amino-N-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide: structure in first source	2.06	1
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	2.06	1	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
thiocarlide thiocarlide: major descriptor (68-85); on-line search PHENYLTHIOUREA/AA (68-85); Index Medicus search THIOCARLIDE (68-85); Antitubercular Agent	2.06	1	thioureas
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.06	1	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
tandutinib [no description available]	2.06	1	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	2.06	1	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.06	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
zd 6474 CH 331: structure in first source	2.06	1	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide [no description available]	2.06	1	aryl sulfide
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide [no description available]	2.06	1	indoles
ver-49009 VER-49009: inhibits heat shock protein 90 molecular chaperone; structure in first source. 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide : An aromatic amide obtained by formal condensation of the carboxy group of 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)pyrazole-3-carboxylic acid with the amino group of ethylamine.	2.06	1	aromatic amide; monochlorobenzenes; monomethoxybenzene; pyrazoles; resorcinols	Hsp90 inhibitor
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.06	1	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.06	1	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.06	1	benzamides
acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.	2.06	1	dihydroxyflavone; monomethoxyflavone	anticonvulsant; plant metabolite
pd 166285 [no description available]	2.06	1
palbociclib [no description available]	2.06	1	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	2.06	1	sulfonamide
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	2.06	1	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680 [no description available]	2.06	1	N-arylpiperazine
cyc 116 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source	2.06	1
1-azakenpaullone 1-azakenpaullone : An organic heterotetracyclic compound that is 7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indole substituted at positions 6 and 9 by oxo and bromo groups respectively.	2.06	1	lactam; organic heterotetracyclic compound; organobromine compound; organonitrogen heterocyclic compound	EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
a 419259 [no description available]	2.06	1
gdp 366 GDP 366: an antineoplastic agent; structure in first source	2.06	1
2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]ethanol [no description available]	2.06	1	thiopurine
a 770041 [no description available]	2.06	1	aromatic amide
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.06	1
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.06	1	quinoxaline derivative
adw 742 [no description available]	2.06	1
gw843682x [no description available]	2.06	1	(trifluoromethyl)benzenes
sb 242235 SB 242235: p38 MAP kinase antagonist	2.06	1
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.06	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
tgx 221 TGX 221: a platelet aggregation inhibitor	2.06	1	pyridopyrimidine
zm 447439 ZM447439 : A member of the class of quinazolines that is quinazoline which is substituted at positions 4, 6 and 7 by a (4-benzamidophenyl)nitrilo group, methoxy group and a 3-(morpholin-4-yl)propoxy group, respectively. It is an ATP-competitive inhibitor of Aurora A and Aurora B kinases with IC50 of 110 nM and 130 nM, respectively.	2.06	1	aromatic ether; benzamides; morpholines; polyether; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	2.06	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib [no description available]	2.06	1	aromatic ether
tae226 TAE226: an adhesion kinase inhibitor, offers an attractive therapeutic approach in ovarian carcinoma; structure in first source	2.06	1	morpholines
tak-715 N-(4-(2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)-2-pyridyl)benzamide: anti-rheumatoid arthritis agent; structure in first source	2.06	1	benzamides
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.06	1	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
ly2090314 LY-2090314 : A member of the class of diazepinoindoles that is 1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indole substituted by piperidin-1-ylcarbonyl, 4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl and fluoro groups at position 2, 7 and 9, respectively. It is a potent ATP-competitive inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3alpha and GSK-3beta. The drug is in clinical development for the treatment of advanced/metastatic cancer.	2.06	1	diazepinoindole; imidazopyridine; maleimides; monofluorobenzenes; piperidinecarboxamide; ureas	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	2.06	1	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
bay 61-3606 [no description available]	2.06	1	pyrimidines
sotrastaurin sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.	2.06	1	indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines	anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent
vx 702 VX 702: a p38 MAP kinase inhibitor	2.06	1	phenylpyridine
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.06	1	methoxybenzenes; substituted aniline
cvt-6883 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: structure in first source	2.06	1
r 1487 [no description available]	2.06	1
nvp-ast487 NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells	2.06	1
abt 869 [no description available]	2.06	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
azd 1152 AZD-1152 : A member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether.	2.06	1	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine : A pyrazolylpiperidine that consists of 4-(pyrazol-1-yl)piperidine carrying a 2-amino-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-5-yl group at the 4-position of the pyrazole ring.. rac-crizotinib : A racemate comprising equimolar amounts of (R)- and (S)-crizotinib. The active (R)-enantiomer acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.	2.06	1	aminopyridine; aromatic ether; dichlorobenzene; organofluorine compound; pyrazolylpiperidine; racemate	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.06	1
osi 906 [no description available]	2.06	1	cyclobutanes; quinolines
mln8054 [no description available]	2.06	1	benzazepine
pf-562,271 [no description available]	2.06	1	indoles
pha 767491 PHA 767491: a Cdc7 inhibitor; structure in first source	2.06	1	pyrrolopyridine
gpi 15427 [no description available]	2.06	1
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.06	1	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
a-484954 A-484954: eEF2K inhibitor; structure in first source	2.06	1
azd 1152-hqpa AZD2811: has antineoplastic activity; structure in first source	2.06	1	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor
nvp-tae684 [no description available]	2.06	1	piperidines
4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid [no description available]	2.46	2
gsk 269962a [no description available]	2.06	1
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [no description available]	2.06	1	indoles
tg101209 [no description available]	2.06	1	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
t-tucb [no description available]	2.04	1
pf 04217903 [no description available]	2.06	1	quinolines
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile [no description available]	2.06	1	pyrrolopyrimidine
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.06	1	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	2.06	1	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
mln 8237 MLN 8237: an aurora kinase A inhibitor	2.06	1	benzazepine
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.06	1	piperazines
PP121 [no description available]	2.06	1	aromatic amine; cyclopentanes; pyrazolopyrimidine; pyrrolopyridine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; tyrosine kinase inhibitor
sns 314 SNS 314: an aurora kinase inhibitor; structure in first source	2.06	1	ureas
gsk 650394 [no description available]	2.06	1	phenylpyridine
thiouredopyrenetrisulfonate N-[1-(methanesulfonyl)piperidin-4-yl]-N'-[4-(trifluoromethoxy)phenyl]urea : A phenylurea that is urea substituted by 1-(methylsulfonyl)piperidin-4-yl and 4-(trifluoromethoxy)phenyl groups at positions 1 and 3 respectively.	2.04	1	phenylureas	EC 3.3.2.10 (soluble epoxide hydrolase) inhibitor
entrectinib entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source. entrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.	2.06	1	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
abt-348 ilorasertib: an antineoplastic agent and protein kinase inhibitor; structure in first source	2.06	1
au1235 [no description available]	2.06	1
chir 258 [no description available]	2.06	1
r 1530 [no description available]	2.06	1
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile: structure in first source. AZD1080 : A member of the class of hydroxyindoles that is 1H-indole substituted by hydroxy, 5-(morpholin-4-ylmethyl)pyridin-2-yl, and cyano groups at positions 2, 3 and 5, respectively. It is a potent, brain permeable inhibitor of human GSK3alpha and GSK3beta with Ki of 6.9 nM and 31 nM, respectively. The drug was being developed by AstraZeneca for the treatment of Alzheimer's disease (clinical trial now discontinued).	2.06	1	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Benign Neoplasms [description not available]	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

1,3-diphenylurea

Description

Cross-References

Synonyms (122)

Roles (2)

Drug Classes (1)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (161)

Molecular Functions (53)

Ceullar Components (39)

Bioassays (82)

Research

Studies (19)

Market Indicators

Research Demand Index: 29.77

Study Types

1,3-diphenylurea

Description

Cross-References

Synonyms (122)

Roles (2)

Drug Classes (1)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (161)

Molecular Functions (53)

Ceullar Components (39)

Bioassays (82)

Research

Studies (19)

Market Indicators

Research Demand Index: 29.77

Study Types

Related Drugs (129)

Related Conditions (6)